Sasamoto Y, Ohno S, Matsuda H
Department of Ophthalmology, Hokkaido University School of Medicine, Sapporo, Japan.
Ophthalmologica. 1990;201(3):162-7. doi: 10.1159/000310145.
We evaluated the significance of corticosteroid therapy on 47 new patients with Vogt-Koyanagi-Harada disease examined in the Uveitis Survey Clinic of the Hokkaido University Hospital. All patients were treated with topical corticosteroids, with or without systemic corticosteroids. 18 patients received systemic corticosteroid as pulse therapy, 20 patients received high-dose corticosteroid starting with prednisolone 200 mg, 2 patients received conventional-dose corticosteroid and 7 patients received no systemic corticosteroid therapy. When we evaluated the results 6 months after the initiation of treatment, anterior chamber inflammation was significantly less in patients with pulse and high-dose corticosteroid therapy than in those without systemic corticosteroid therapy. Furthermore, final visual acuity was significantly better in patients with pulse and high-dose corticosteroid than in those without them. However, there was no significant difference between patients with pulse therapy and those with high-dose corticosteroid therapy. The findings are in support of systemic corticosteroid therapy (pulse and high-dose) in the treatment of Vogt-Koyanagi-Harada disease.
我们评估了皮质类固醇疗法对北海道大学医院葡萄膜炎诊疗门诊所诊治的47例新发性小柳原田病患者的意义。所有患者均接受了局部皮质类固醇治疗，部分患者联合或未联合全身皮质类固醇治疗。18例患者接受了全身皮质类固醇脉冲疗法，20例患者从200毫克泼尼松龙开始接受高剂量皮质类固醇治疗，2例患者接受常规剂量皮质类固醇治疗，7例患者未接受全身皮质类固醇治疗。当我们在治疗开始6个月后评估结果时，接受脉冲和高剂量皮质类固醇治疗的患者前房炎症明显少于未接受全身皮质类固醇治疗的患者。此外，接受脉冲和高剂量皮质类固醇治疗的患者最终视力明显优于未接受治疗的患者。然而，接受脉冲疗法的患者与接受高剂量皮质类固醇治疗的患者之间没有显著差异。这些发现支持全身皮质类固醇疗法（脉冲和高剂量）用于治疗小柳原田病。
